{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:43:34Z","timestamp":1789879414011,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.07.018","type":"journal-article","created":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T10:30:15Z","timestamp":1531650615000},"page":"5160-5165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour"],"prefix":"10.1016","volume":"36","author":[{"given":"Ellen","family":"Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Miriam","family":"Elfstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedda","family":"Haugen Cange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Englund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Spar\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.07.018_b0005","unstructured":"Folkh\u00e4lsomyndigheten. Statistik f\u00f6r HPV-vaccinationer [Internet]. [updated 2016-09-09; cited 2017 13 apr 2017]. Available from: https:\/\/www.folkhalsomyndigheten.se\/folkhalsorapportering-statistik\/statistikdatabaser-och-visualisering\/vaccinationsstatistik\/statistik-for-hpv-vaccinationer\/."},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.018_b0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/jir285","article-title":"Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity","volume":"204","author":"Brisson","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.018_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089974","article-title":"Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys","volume":"9","author":"Burger","year":"2014","journal-title":"PloS One"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2018.07.018_b0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2013.07.015","article-title":"A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types","volume":"445","author":"Bzhalava","year":"2013","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.018_b0025","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/ijc.29082","article-title":"EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection","volume":"136","author":"Giuliano","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2018.07.018_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2018.07.018_b0035","series-title":"HPV","article-title":"Monographs on the evaluation of carcinogenic risks to humans","author":"IARC","year":"2012"},{"issue":"11","key":"10.1016\/j.vaccine.2018.07.018_b0040","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.018_b0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ijc.25699","article-title":"Trends in head and neck cancer incidence in Denmark, 1978\u20132007: focus on human papillomavirus associated sites","volume":"129","author":"Blomberg","year":"2011","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.018_b0050","first-page":"1343","article-title":"Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992\u20132009","volume":"23","author":"Forte","year":"2012","journal-title":"Cancer Causes Control: CCC"},{"issue":"11","key":"10.1016\/j.vaccine.2018.07.018_b0055","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/ijc.22177","article-title":"Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer","volume":"119","author":"Hammarstedt","year":"2006","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2018.07.018_b0060","first-page":"1397","article-title":"Time trends in pharyngeal cancer incidence in Norway 1981\u20132005: a subsite analysis based on a reabstraction and recoding of registered cases","volume":"21","author":"Mork","year":"2010","journal-title":"Cancer Causes Control: CCC"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.018_b0065","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1308\/003588410X12699663904871","article-title":"Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985\u20132006","volume":"92","author":"Reddy","year":"2010","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.vaccine.2018.07.018_b0070","unstructured":"Regionala cancercentrum i samverkan. Huvud- och halscancer. Nationellt v\u00e5rdprogram. Nationellt v\u00e5rdprogram, 2015; 2017."},{"key":"10.1016\/j.vaccine.2018.07.018_b0075","unstructured":"Svenskt kvalitetsregister f\u00f6r huvud- och halscancer. (Swedish head and neck cancer register SweHNCR). Huvud- och Halscancer. \u00c5rsrapport nationellt kvalitetsregister 2016. Diagnos\u00e5r 2008\u20132015. G\u00f6teborg: Regionalt Cancercentrum V\u00e4st; 2016."},{"key":"10.1016\/j.vaccine.2018.07.018_b0080","unstructured":"Regionalt cancercentrum Uppsala \u00d6rebro. Peniscancer. Nationellt v\u00e5rdprogram. Regionala cancercentrum i samverkan; 2016."},{"key":"10.1016\/j.vaccine.2018.07.018_b0085","unstructured":"Socialstyrelsen. Cancerincidens i Sverige 2014 \u2013 Nya diagnosticerade cancerfall \u00e5r 2014. Stockholm: Socialstyrelsen; 2015 [Artikelnummer: 2015-12-26]."},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.018_b0090","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1158\/1055-9965.EPI-14-0687","article-title":"Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study","volume":"23","author":"Soderlund-Strand","year":"2014","journal-title":"Cancer Epidemiol Biomark Prevent: Publ Am Assoc Cancer Res"},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.018_b0095","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/ijc.30035","article-title":"Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study","volume":"138","author":"Herweijer","year":"2016","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2018.07.018_b0100","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/infdis\/jis405","article-title":"Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability","volume":"206","author":"Leval","year":"2012","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.018_b0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1473-3099(16)30116-5","article-title":"Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study","volume":"17","author":"Chow","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2018.07.018_b0110","article-title":"Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I)","author":"Lehtinen","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.018_b0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3201\/eid2201.150736","article-title":"Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009\u20132013","volume":"22","author":"Cameron","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.018_b0120","article-title":"Vaccination protects against invasive HPV-associated cancers","author":"Luostarinen","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2018.07.018_b0125","unstructured":"Socialstyrelsen. Cancerregistret. Available from: http:\/\/www.socialstyrelsen.se\/register\/halsodataregister\/cancerregistret."},{"key":"10.1016\/j.vaccine.2018.07.018_b0130","unstructured":"NKCx. Nationellt Kvalitetsregister f\u00f6r Cervixcancerprevention. Available from: http:\/\/nkcx.se\/index_e.htm."},{"issue":"46","key":"10.1016\/j.vaccine.2018.07.018_b0135","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.018_b0140","unstructured":"Folkh\u00e4lsomyndigheten. MSM2013 \u2013 En studie om sex, hiv och h\u00e4lsa bland m\u00e4n som har sex med m\u00e4n i Sverige; 2015."},{"key":"10.1016\/j.vaccine.2018.07.018_b0145","unstructured":"World Health Organization. Safety of human papillomavirus vaccines. Available from: http:\/\/www.who.int\/vaccine_safety\/committee\/topics\/hpv\/en\/."},{"key":"10.1016\/j.vaccine.2018.07.018_b0150","unstructured":"Tandv\u00e5rds och l\u00e4kemedelsf\u00f6rm\u00e5nsverket. L\u00e4kemedelsf\u00f6rm\u00e5nsn\u00e4mndens allm\u00e4nna r\u00e5d om ekonomiska utv\u00e4rderingar; 2003. Available from: https:\/\/www.tlv.se\/Upload\/Lagar_och_foreskrifter\/LAG-lfnar-2003-2.pdf."},{"key":"10.1016\/j.vaccine.2018.07.018_b0155","unstructured":"Myers EG, Green S, Lipkus I. Patient preferences for health states related to HPV-infection: visual analogue scales vs time trade-off elicitation [abstract]. In: Proceeding of the 21st international papillomavirus conference, Mexico City, Mexico; 2004."},{"issue":"11","key":"10.1016\/j.vaccine.2018.07.018_b0160","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"7","key":"10.1016\/j.vaccine.2018.07.018_b0165","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/sextrans-2011-050161","article-title":"Quality of life valuations of HPV-associated cancer health states by the general population","volume":"88","author":"Conway","year":"2012","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2018.07.018_b0170","unstructured":"Stockholms l\u00e4ns landsting. Upphandlade l\u00e4kemedel, vacciner; 2017. Available from: http:\/\/www.janusinfo.se\/Rutiner\/Upphandlade-lakemedel\/."},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.018_b0175","doi-asserted-by":"crossref","first-page":"e1001147","DOI":"10.1371\/journal.pmed.1001147","article-title":"Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models","volume":"8","author":"Bogaards","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.07.018_b0180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1471-2334-14-351","article-title":"Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program","volume":"14","author":"Pearson","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.018_b0185","doi-asserted-by":"crossref","first-page":"866","DOI":"10.12688\/f1000research.10691.1","article-title":"Human papillomavirus vaccination: the population impact","volume":"6","author":"Lee","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.vaccine.2018.07.018_b0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12962-017-0080-9","article-title":"Cost-effectiveness of human papillomavirus vaccination in Germany","volume":"15","author":"Damm","year":"2017","journal-title":"Cost Eff Resour Alloc"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.018_b0195","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/infdis\/jix272","article-title":"Health and economic impact of a tender-based, sex-neutral human papillomavirus 16\/18 vaccination program in the Netherlands","volume":"216","author":"Qendri","year":"2017","journal-title":"J Infect Dis"},{"issue":"37","key":"10.1016\/j.vaccine.2018.07.018_b0200","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1016\/j.vaccine.2017.07.078","article-title":"Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective","volume":"35","author":"Zhang","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.018_b0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/14760584.2017.1256778","article-title":"The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases","volume":"16","author":"Suijkerbuijk","year":"2017","journal-title":"Expert Rev Vacc"},{"issue":"48","key":"10.1016\/j.vaccine.2018.07.018_b0210","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1016\/j.vaccine.2011.02.091","article-title":"The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia","volume":"29","author":"Smith","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.018_b0215","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv282","article-title":"Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States","volume":"108","author":"Brisson","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.018_b0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.mbs.2013.01.006","article-title":"When can a deterministic model of a population system reveal what will happen on average?","volume":"243","author":"Gustafsson","year":"2013","journal-title":"Math Biosci"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.018_b0225","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jval.2015.08.010","article-title":"Cost-Effectiveness analysis of universal human papillomavirus vaccination using a dynamic bayesian methodology: the BEST II study","volume":"18","author":"Haeussler","year":"2015","journal-title":"Value Health"},{"issue":"22","key":"10.1016\/j.vaccine.2018.07.018_b0230","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.vaccine.2014.02.071","article-title":"Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand","volume":"32","author":"Blakely","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.018_b0235","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/14737167.2014.881253","article-title":"Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis","volume":"14","author":"Bresse","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"42","key":"10.1016\/j.vaccine.2018.07.018_b0240","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2018.07.018_b0245","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2013.06.064","article-title":"Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study","volume":"31","author":"Brisson","year":"2013","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2018.07.018_b0250","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.vaccine.2014.07.099","article-title":"Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study","volume":"32","author":"Laprise","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:28:19Z","timestamp":1759400899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18309484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":50,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X18309484"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}